Cardiovascular hemodynamics after opsonic alpha-2-surface binding glycoprotein therapy in injured patients.
Depression of reticuloendothelial (RE) phagocytic function has been clearly documented following trauma and operation. This phagocytic failure is mediated in part by depletion of an opsonic glycoprotein. Depletion of this opsonic protein may result in prolonged blood retention of potentially harmful particulates that may interfere with the microcirculation and may possibly result in altered organ function. Isolation and identification of this opsonic protein has led to the finding of the identity between opsonic glycoprotein and cold insoluble globulin (CIg) or so-called plasma fibronectin. Since CIg is concentrated in cryoprecipitate, this blood component was used as a readily available source of opsonic protein for replacement studies. Nine patients were studied following a 1-hour infusion of cryoprecipitate obtained from 10 units of plasma and suspended in a volume of 250 ml. Both the pulmonary shunt fraction and the fraction of dead space ventilation decreased significantly (P = 0.02) after cryoprecipitate administration. Limb blood flow (P = 0.001), limb oxygen consumption (P = 0.001), and reactive hyperemia of the limb (P = 0.05) increased significantly following cryoprecipitate infusion. Cardiac output, total oxygen consumption did not change consistently. The data demonstrate that the infusion of cryoprecipitate resulted in improved pulmonary and microcirculatory function--possibly due to opsonic glycoprotein replacement.
D002302:Cardiac Output / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007118:Immunoassay; D007866:Leg / Q000098:blood supply; D008833:Microcirculation / Q000187:drug effects; D009895:Opsonin Proteins / Q000032:analysis / Q000172:deficiency / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects; D010587:Phagocytosis; D011652:Pulmonary Circulation / Q000187:drug effects; D012039:Regional Blood Flow / Q000187:drug effects; D012126:Respiratory Dead Space / Q000187:drug effects; D013990:Tidal Volume; D014947:Wounds and Injuries / Q000276:immunology / Q000503:physiopathology*; D000511:alpha-Macroglobulins / Q000032:analysis / Q000172:deficiency / Q000627:therapeutic use*
D009895:Opsonin Proteins; D000511:alpha-Macroglobulins